Uridine triacetate

Uridine triacetate
Clinical data
Trade names Vistogard, Xuriden
Routes of
administration		 Oral granules
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism Pyrimidine catabolic pathway
Onset of action Tmax = 2–3 hours
Elimination half-life 2–2.5 hours
Excretion Renal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ECHA InfoCard 100.021.710 Edit this at Wikidata
Chemical and physical data
Formula C15H18N2O9
Molar mass 370.31 g·mol−1
3D model (JSmol)

Uridine triacetate (INN),[1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine[2] used:

  • in the treatment of hereditary orotic aciduria (brand name Xuriden /ˈzʊərədɛn/ ZOOR-ə-den);[3]
  • to treat patients following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).[4][5][6]

Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. Also, It was granted breakthrough therapy designation by FDA in 2015.

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. p. 92. Retrieved 12 March 2017.
  2. ↑ "Uridine triacetate — DrugBank Page". 12 March 2017.
  3. ↑ "Xuriden (uridine triacetate) Oral Granules. Full Prescribing Information" (PDF). Wellstat Therapeutics Corporation. Gaithersburg, MD 20878. Retrieved 12 March 2017.
  4. ↑ "Vistogard (uridine triacetate) Oral Granules. Full Prescribing Information" (PDF). Wellstat Therapeutics Corporation. Gaithersburg, MD 20878. Retrieved 12 March 2017.
  5. ↑ "BTG Announces FDA Approval of Vistogard® (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine". BTG International Ltd. 11 December 2015. Retrieved 12 March 2017.
  6. ↑ "Approved Drugs — Uridine Triacetate". U.S. Food and Drug Administration. Retrieved 12 March 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.